FDA makes it easier for biosimilars to obtain interchangeability designations
The FDA on Thursday began easing the process for biosimilar developers to demonstrate interchangeability with their brand-name biologics.
The agency previously required studies to prove …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
